GRAIL, Inc. (NASDAQ:GRAL) Receives $90.17 Consensus Target Price from Analysts

Shares of GRAIL, Inc. (NASDAQ:GRAL) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $82.00.

A number of equities analysts recently weighed in on the company. Robert W. Baird set a $82.00 price target on GRAIL in a report on Friday, February 20th. Morgan Stanley decreased their price objective on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Guggenheim lifted their target price on shares of GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Finally, TD Cowen upgraded GRAIL from a “hold” rating to a “buy” rating and set a $65.00 price target for the company in a research report on Wednesday.

Insiders Place Their Bets

In other GRAIL news, CFO Aaron Freidin sold 9,573 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $50.17, for a total transaction of $480,277.41. Following the transaction, the chief financial officer owned 309,622 shares of the company’s stock, valued at approximately $15,533,735.74. The trade was a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, President Joshua J. Ofman sold 17,002 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $50.16, for a total transaction of $852,820.32. Following the completion of the sale, the president directly owned 436,508 shares of the company’s stock, valued at approximately $21,895,241.28. This trade represents a 3.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 79,294 shares of company stock valued at $3,955,224. Insiders own 1.85% of the company’s stock.

Hedge Funds Weigh In On GRAIL

Institutional investors have recently bought and sold shares of the company. Rockefeller Capital Management L.P. grew its stake in shares of GRAIL by 18.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 68,577 shares of the company’s stock worth $5,870,000 after acquiring an additional 10,565 shares in the last quarter. Osbon Capital Management LLC acquired a new stake in GRAIL in the fourth quarter valued at $51,000. Fund Advisors of America Inc FL purchased a new stake in shares of GRAIL during the 4th quarter worth approximately $299,000. DUTCH ASSET Corp acquired a new stake in GRAIL during the 4th quarter worth $532,000. Finally, Corient Private Wealth LLC boosted its stake in GRAIL by 60.4% in the fourth quarter. Corient Private Wealth LLC now owns 9,274 shares of the company’s stock valued at $794,000 after acquiring an additional 3,491 shares in the last quarter.

GRAIL Price Performance

NASDAQ GRAL opened at $46.84 on Monday. GRAIL has a 1 year low of $20.44 and a 1 year high of $118.84. The company has a fifty day moving average of $79.59 and a 200 day moving average of $78.19. The company has a market capitalization of $1.92 billion, a PE ratio of -4.19 and a beta of 5.18.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) EPS for the quarter, topping analysts’ consensus estimates of ($3.33) by $0.89. The business had revenue of $43.60 million for the quarter, compared to analysts’ expectations of $43.33 million. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%. Research analysts expect that GRAIL will post -15.15 earnings per share for the current year.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.